Gilead Q2'25 Financial Results: Key Takeaways and Pipeline Updates

Gilead Q2'25 Financial Results: Key Takeaways and Pipeline Updates

• 1. 10 December 2024 Q225 Financial Results August 7, 2025

• 2. Forward-Looking Statements Statements included in this press release that are not historical in nature are forward-looking statements within the meaning ofthe Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead’s ability to achieve its full year 2025 financial guidance, including as a result of the uncertainty of the amount and timing of Veklury revenues, the impact of the Inflation Reduction Act, changes in U.S. regulatory or legislative policies, and changes in U.S. trade policies, including tariffs; Gilead’s ability to make progress on any of its long-term ambitions or priorities laid out in its corporate strategy; Gilead’s ability to accelerate or sustain revenues for its virology, oncology and other programs; Gilead’s ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements, including the acquisitions of MYR, and the arrangements with Arcellx, Kymera and the Global Fund; patent protection and estimated loss of exclusivity for our products and product candidates; Gilead’s ability to initiate, progress or complete clinical trials within currently anticipated timeframes or at all, the possibility of unfavorable results from ongoing and additional clinical trials, including those involving Livdelzi, Trodelvy, Yescarta, Yeztugo (lenacapavir), anito-cel, bulevirtide, GS-1720, and GS-4182 (such as the ASCENT-03, ASCENT-04, ASSURE, iMMagine-1, MYR301, PURPOSE 1, PURPOSE 2, WONDERS-1, and WONDERS-2 studies), and the risk that safety and efficacy data from clinical trials may not warrant further development of Gilead’s product candidates or the product candidates of Gilead’s strategic partners; Gilead’s ability to resolve the issues cited by the FDA in the clinical hold on the GS-1720 and GS-4182 trials to the satisfaction of the FDA and the risk that FDA may not remove the clinical hold, in whole or in part, in a timely manner or at all; Gilead’s ability to submit new drug applications for new product candidates or expanded indications in the currently anticipated timelines; Gilead’s ability to receive or maintain regulatory approvals in a timely manner or at all, including for additional approvals for lenacapavir for HIV PrEP, and the risk that any such approvals, if granted, may be subject to significant limitations on use and may be subject to withdrawal or other adverse actions by the applicable regulatory authority; Gilead’s ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead’s products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of Gilead’s products over other therapies and may therefore be reluctant to prescribe the products, including Yeztugo; Gilead’s ability to effectively manage the access strategy relating to lenacapavir for HIV PrEP, subject to necessary regulatory approvals; and other risks identified from time to time in Gilead’s reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Further, results for the quarter ended June30, 2025 are not necessarily indicative of operating results for any future periods. Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. The reader is cautioned that forward-looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forwardlooking statements speak only as of the date hereof or as of the dates indicated in the statements. Gilead owns or has rights to various trademarks, copyrights and trade names used in its business, including the following: GILEAD®, GILEAD SCIENCES®, KITETM, AMBISOME®, ATRIPLA®, BIKTARVY®, CAYSTON®, COMPLERA®, DESCOVY®, DESCOVY FOR PREP®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPCLUDEX®, HEPSERA®, JYSELECA®, LETAIRIS®, LIVDELZI®/LYVDELZI®, ODEFSEY®, SOVALDI®, STRIBILD®, SUNLENCA®,TECARTUS®, TRODELVY®, TRUVADA®, TRUVADA FOR PREP®, TYBOST®, VEKLURY®, VEMLIDY®, VIREAD®, VOSEVI®, YESCARTA®, YEZTUGO® and ZYDELIG®. This report may also refer to trademarks, service marks and trade names of other companies. 2

• 3. Contents 3 Key Takeaways 4-5 Commercial Results Pipeline Updates Financial Results Appendix 6-14 15-20 21-26 28-35

• 4. Q225 Key Takeaways Daniel O’Day Chairman & Chief Executive Officer

• 5. Gilead Q225 - Key Takeaways 1 Business Performance 3 2 • Total Product Sales excluding Veklury up 4% YoY to $6.9B, driven by HIV, Livdelzi, and Trodelvy • Total HIV up 7% YoY; Biktarvy up 9% YoY and Descovy up 35% YoY • Total Oncology up 1% YoY; Trodelvy up 14% YoY; Cell Therapy down 7% YoY • Strong top and bottom line results reflected in increased 2025 revenue and EPS guidance 5 • FDA approval of Yeztugo (lenacapavir), a twice-yearly injection for HIV prevention • Initiated Phase 3 PURPOSE-365 study for evaluating once-yearly lenacapavir for PrEP • Clinically meaningful Phase 3 ASCENT-03 & -04 data for Trodelvy1 in 1L mTNBC; FDA filings in ~2H 2025 • Updated next-generation CAR T data at EHA 2025; advancing KITE-363 development Looking Ahead • Ongoing Yeztugo launch amid growing PrEP market • Positive CHMP opinion for twice-yearly lenacapavir for PrEP; EC decision expected 2H 2025 • Phase 3 updates for ARTISTRY-1 & ARTISTRY-2 for once-daily BIC/LEN expected in 2H 2025 • Phase 2 iMMagine-1 update for anito-cel in MM expected in 2H 2025; target launch in 2026 Clinical Updates 1. Trodelvy + Pembrolizumab for ASCENT-04 in PD-L1+ (CPS≥10) 1L mTNBC. Note: YoY reflects Q225 vs Q224. BIC/LEN – bictegravir + lenacapavir, CHMP – Committee for Medicinal Products for Human Use, EC – European Commission, EHA – European Hematology Association; MM – multiple myeloma, PrEP – pre-exposure prophylaxis.

• 6. Johanna Mercier Chief Commercial Officer Commercial Results & Market Dynamics

• 7. Solid Base Business Performance in Q225 HIV Product Sales +7% YoY, +11% QoQ +7% YoY $5.1B HIV -44% YoY $121M Veklury -28% YoY $202M Other +14% YoY $364M Trodelvy -7% YoY $485M Cell Therapy -4% YoY $795M Liver Disease $5.1B Note: YoY reflects Q225 vs Q224 and QoQ reflects Q225 vs Q125. Oncology Product Sales $849M +1% YoY, +12% QoQ Total Product Sales excluding Veklury $6.9B +4% YoY, +10% QoQ Total Product Sales $7.1B +2% YoY, +7% QoQ 7

• 8. $3,821 $4,161 $4,532 $3,664 $4,096 $571 $570 $603 $553 $624 $353 $342 $317 $370 $368 $4,745 $5,073 $5,452 $4,587 $5,088 Q224 Q324 Q424 Q125 Q225 U.S. Europe Rest of World HIV: Strong Demand-Driven YoY Growth 8 • YoY reflects increased demand and higher average realized price • QoQ reflects seasonal inventory dynamics, higher average realized price and higher demand Sales QoQ +11% Sales YoY +7% Product Sales ($M) Note: YoY reflects Q225 vs Q224 and QoQ reflects Q225 vs Q125.

• 9. Q225 sales: $3.5B, +9% YoY, +12% QoQ U.S. Market Share 51% U.S. Treatment Market Growth YoY 2-3% Q225 sales: $653M; +35% YoY, +11% QoQ U.S. Market Share >40% U.S. PrEP Market Growth YoY ~15% • Remains #1 prescribed regimen for new starts and treatment switches across most major markets • YoY driven by higher demand • QoQ reflects seasonal inventory dynamics and higher average realized price, as well as higher demand • Descovy for PrEP maintaining share despite availability of other regimens, including generics • YoY driven by higher average realized price and demand • QoQ primarily driven by seasonal inventory dynamics and higher demand Share Growth for HIV Treatment & PrEP Biktarvy received FDA approval to expand its label to include the treatment of people with HIV (PWH) with an antiretroviral treatment (ART) history who are not virologically suppressed, with no known or suspected resistance to the integrase strand inhibitor (INSTI) class, emtricitabine or tenofovir. Note: YoY reflects Q225 vs Q224 and QoQ reflects Q225 vs Q125. Biktarvy (bictegravir 50 mg, emtricitabine 200 mg, tenofovir alafenamide 25 mg) tablets. Descovy (emtricitabine 200 mg, tenofovir alafenamide 25 mg) tablets. PrEP – pre-exposure prophylaxis. 9

• 10. Yeztugo: Now Approved in U.S. for HIV PrEP 10 Note: In the U.S., Yeztugo is approved for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents (≥35 kg) who are at risk for HIV-1 acquisition. ~hours First prescription written 24 hours days First dose administered Upon Approval: First product shipped FDA Approval 18 June 2025 U.S. Launch June 2025 WHO Recommendation July 2025 EU CHMP Opinion July 2025 European Commission Decision Expected 2H25

• 11. FY25 HIV Guidance Updated to Reflect YTD Strength 11 HIV Revenue Illustrative Guidance >7% YoY • Strong performance of Biktarvy and Descovy driving increased sales guidance for FY25 • HIV sales now expected to grow~3% YoY • No changes to: • Medicare Part D assumptions • Yeztugo assumptions, given launch recency • Policy environment assumptions $17.2B $18.2B $19.6B FY22 FY23 FY24 FY25 August Guidance Total HIV Sales Impact of IRA Part D Reform Product Sales ($B) >7% (Illustrative vs FY24) +~3% (vs FY24)

• 12. $431 $393 $391 $335 $413 $142 $132 $134 $168 $170 $259 $207 $194 $256 $211 $832 $733 $719 $758 $795 Q224 Q324 Q424 Q125 Q225 U.S. Europe Rest of World Liver Disease: Growing Livdelzi Contributions Livdelzi (seladelpar) capsules. HCV includes Epclusa, the authorized generic version of Epclusa, Harvoni, the authorized generic version of Harvoni, Sovaldi and Vosevi. HBV includes Hepsera (adefovir dipivoxil), Vemlidy (tenofovir alafenamide), and Viread (tenofovir disoproxil fumarate). HDV includes Hepcludex (bulevirtide). Note: Received full marketing authorization from EC for Hepcludex (bulevirtide) for the treatment of adults with chronic HDV and compensated liver disease. Bulevirtide remains the only approved treatment for chronic hepatitis delta virus (“HDV”) in the EU and is not approved in the U.S. Note: YoY reflects Q225 vs Q224 and QoQ reflects Q225 vs Q125. 12 • -4% YoY reflects lower HCV sales, partially offset by higher demand across Livdelzi, HDV and HBV • +5% QoQ reflects higher demand for Livdelzi and higher average realized price for HCV, partially offset by lower HCV volume • Ongoing launch activities for Livdelzi in the U.S. and Europe U.S. HCV market Share >60% Q225 Livdelzi sales $78M Product Sales ($M)

• 13. Trodelvy: Continued Strength in mBC 1. U.S. and EU. Trodelvy (sacituzumab govitecan-hziy) for injection. Note: YoY reflects Q225 vs Q224 and QoQ reflects Q225 vs Q125. mBC – metastatic breast cancer. mTNBC – metastatic triple-negative breast cancer. mUC – metastatic urothelial cancer. 13 $224 $226 $247 $181 $224 $69 $80 $77 $75 $96 $26 $26 $31 $37 $320 $44 $332 $355 $293 $364 Q224 Q324 Q424 Q125 Q225 U.S. Europe Rest of World Product Sales ($M) • +14% YoY and +24% QoQ reflecting continued strength in mBC more than offsetting lower YoY mUC sales • Strong demand outside of U.S. both YoY and QoQ Countries Approved 59 2L mTNBC1 share #1

• 14. Cell Therapy: Evolving Competitive Landscape $414 $387 $390 $386 $393 $107 $98 $98 $78 $92 $521 $485 $488 $464 $485 Q224 Q324 Q424 Q125 Q225 Yescarta Tecartus 14 Yescarta (axicabtagene ciloleucel) suspension for IV infusion. Tecartus (brexucabtagene autoleucel) suspension for IV infusion. Note: YoY reflects Q225 vs Q224 and QoQ reflects Q225 vs Q125. ATC – authorized treatment center. Product Sales ($M) • -7% YoY, reflecting lower demand, partially offset by higher average realized price • +5% QoQ, driven by favorable FX impact as well as increased demand for Yescarta in the U.S. and Tecartus globally Patients treated to date >31K ATCs Globally >570

• 15. Dietmar Berger, MD, PhD Chief Medical Officer Pipeline Updates

• 16. Strong Execution Driving Clinical Momentum 16 CHMP – Committee for Medicinal Products for Human Use, EC – European Commission, EHA – European Hematology Association Positive Regulatory Updates in Virology & Clinical Data Readouts Across Oncology 2H 2025 Updates Positive CHMP Opinion July 2025 FDA Approval June 2025 ASCENT-04 ASCO Update June 2025 ASCENT-04 & -03 Topline April / May 2025 iMMagine-1 EHA Update June 2025 Next Gen CAR T ASCO Update Q2 2025 June 2025 Update EC Regulatory Decision ASCENT-03 & ASCENT-04 Filing iMMagine-1Pivotal Data

• 17. PrEP Treatment Daily Weekly Monthly Quarterly TwiceYearly OnceYearly HIV: Advancing Leading Clinical Pipeline Note: These proposed launch dates are for investigational products that are subject to regulatory review and approval. Timing of estimated product launches are subject to change. Potential future programs are indicated in dashed boxes. bNAb – broadly neutralizing antibody, IM – intramuscular, INSTI – integrase inhibitor, and SC – subcutaneous 17 Phase 1 Phase 2 Phase 3 WONDERS-1 GS-4182/GS-1720 + Complex Regimens FDA APPROVED PURPOSE-1 & PURPOSE-2 SC lenacapavir ~2030 ~2027 ISLEND-1 & ISLEND-2 lenacapavir/islatravir ARTISTRY-1 & ARTISTRY-2 bictegravir/lenacapavir lenacapavir + bNAbs ~2027 ~2029-2030 ~2031-2033 ~2031-2033 WONDERS-1 & WONDERS-2 Program on Clinical Hold teropavimab + zinlirvimab (bNAbs) lenacapavir + GS-1614 GS-1614 (islatravir pro-drug) GS-3107/INSTI GS-3107 (lenacapavir pro-drug) lenacapavir + INSTI (GS-1219 or GS-3242) ~2031-2033 PURPOSE-365 IM lenacapavir ~2028 GS-1219 or GS-3242

• 18. 1XXXX Note: The use of Trodelvy with or without pembrolizumab in 1L mTNBC is investigational and has not been approved anywhere globally. 1. Trodelvy is approved in 2L+ mTNBC and pre-treated HR+/HER2- mBC. 2. Trodelvy’s use in non-small cell lung cancer, small cell lung cancer, and endometrial cancer is investigational and has not been approved anywhere globally. ADC – antibody-drug conjugate, mPFS – median progression-free survival, mTNBC – metastatic triple negative breast cancer, SoC – standard of care Trodelvy: Potential to Change Practice in 1L mTNBC 18 Only ADC to demonstrate statistically significant and clinically meaningful PFS benefit in 1L mTNBC ASCENT-03 Trodelvy 1L mTNBC – not candidate for PD-(L)1 inhibitors ASCENT-04 Trodelvy + Pembrolizumab 1L mTNBC – PD-L1+ (CPS≥10) Clinical Programs Across Multiple Tumor Types: Breast Cancer1 Non-Small Cell Lung Cancer2 Small Cell Lung Cancer2 Endometrial Cancer2

• 19. Advancing Next Wave of CAR T Treatments 19 Note: anito-cel (in partnership with Arcellx), KITE-363, KITE-197, KITE-753 are investigational cell therapies and are not approved for any indication. FIT – fast-in-time Anito-cel Next Generation CAR T iMMagine-1 4L+ R/R MM Topline readout ASH 2024 Data update EHA 2025 Data update Expected 2H25 Target launch 2026 EHA Oral Presentation (May cutoff) • Consistent and compelling clinical profile across efficacy and safety • No delayed neurotoxicity Lymphomas Selection of go-forward CAR T in 2H25 Kite-363 (CD19/CD20) Bicistronic-CAR Kite-197 (CD19) FIT-CAR Kite-753 (CD19/CD20) Bicistronic & FIT-CAR Autoimmune Selected for go-forward for clinical trials Kite-363 (CD19/CD20) Bicistronic-CAR

• 20. Program Trial Indication Update Status Lenacapavir PURPOSE 1 & 2 Q6M LAI HIV PrEP EC Decision PURPOSE 365 Q12M LAI HIV PrEP Phase 3 FPI BIC/LEN ARTISTRY-1 QD Oral HIV Tx Phase 3 update ARTISTRY-2 QD Oral HIV Tx Phase 3 update Anito-cel iMMagine-1 4L + R/R MM Phase 2 update 1H25 2H25 Program Trial Indication Update Status Yeztugo® (Lenacapavir) PURPOSE 1 & 2 Q6M LAI HIV PrEP FDA Decision GS-1720 / GS-4182 WONDERS-11 QW LAO HIV Tx Phase 2 update Livdelzi RESPONSE Primary Biliary Cholangitis EC Decision Trodelvy ASCENT-03 1L mTNBC (PD-L1-) Phase 3 update ASCENT-04 1L mTNBC (PD-L1+) Phase 3 update EVOKE-SCLC ES-SCLC Phase 3 FPI 20 Key 2025 Milestones Livdelzi (seladelpar). Trodelvy (sacituzumab govitecan-hziy). 1. Program timelines pending resolution of GS-1720 and GS-4182 clinical holds. BIC – bictegravir, ES-SCLC – extensive-stage small cell lung cancer, FPI – first patient in, LAI – long-acting injectable, LAO – longacting oral, LEN – lenacapavir, mTNBC - metastatic triple-negative breast cancer, PD-L1 - programmed death-ligand 1, PrEP - pre-exposure prophylaxis, Q6M – twice yearly, Q12M – annual, QD – daily, QW – weekly, R/R MM – relapsed or refractory multiple myeloma, Tx – treatment. Completed Clinical Hold On Track New Since Last Update

• 21. Andrew Dickinson Chief Financial Officer Financial Results

• 22. $214 $121 $6,698 $6,934 $6,912 Q224 Q225 Continued Strength Across the Base Business • HIV +7% YoY, inc. Biktarvy +9% and Descovy +35% • Trodelvy +14% YoY • Livdelzi sales almost doubled QoQ to $78M Product Sales, excluding Veklury +4% YoY +10% QoQ Total Product Sales +2% YoY +7% QoQ • Reflecting 44% lower Veklury sales due to fewer COVID-19 related hospitalizations Note: YoY reflects Q225 vs Q224 and QoQ reflects Q225 vs Q125. Product Sales ($M) 22 Veklury -44% Base Business +4% $7,054

• 23. Q225 Non-GAAP Data In millions, except percentages and per share amounts Q224 Q225 YoY Change COGS $965 $922 -4% Product Gross Margin 86% 87% 89bps R&D $1,335 $1,450 9% Acquired IPR&D $38 $61 NM SG&A $1,351 $1,358 Flat Non-GAAP Operating Expenses $2,724 $2,869 5% Non-GAAP Operating Income $3,265 $3,290 1% Operating Margin 47% 46% -49bps Effective Tax Rate 18% 19% 96bps Non-GAAP Net Income attributable to Gilead $2,519 $2,521 Flat Non-GAAP Diluted EPS attributable to Gilead $2.01 $2.01 Flat Shares used in per share calculation-diluted 1,251 1,255 • R&D increase driven by investment in clinical manufacturing and studies; no change to expectation for flat R&D in FY25 vs FY24 • Acquired IPR&D primarily reflects Kymera collaboration • SG&A primarily reflects higher HIV promotional expenses offset by lower corporate expenses Disciplined Expense Management 23 Please refer to accompanying press release for disclosures about our use of non-GAAP financial measures and GAAP to non-GAAP reconciliations. Note: YoY reflects Q225 vs Q224. NM – not meaningful,

• 24. FY25 Guidance: Increased Base Business Expectations 24 Product Sales Excluding Veklury ($B mid-point) FY25 April Guidance August Guidance Raise FY25 August Illustrative Guidance +~4% + ~7% (vs FY24) FY25 August Guidance Medicare Part D Redesign ~$27B +$0.5B $27.5B $1.1B + ~3% (vs FY24) • Increase of $500M reflecting strong YTD results and higher FY25 base business expectations, including: • Stronger HIV growth of +~3% YoY, driven by Biktarvy and Descovy YTD performance • FX tailwinds • Cell therapy now expected to decline modestly • There is no change to assumptions for: • ~$1.1B impact from Medicare Part D Redesign; • Yeztugo, given recency of launch • Tariffs and broader policy environment Product Sales Excluding Veklury

• 25. 11 Feb 2025 24 April 2025 7 August 2025 Total Product Sales ~$28.2B - $28.6B No change ~$28.3B - $28.7B Product Sales exVeklury ~$26.8B - $27.2B No change ~$27.3B - $27.7B Veklury Sales ~$1.4B No change ~$1.0B Non-GAAP Product Gross Margin ~85 - 86% No change ~86% R&D Expense ~Flat No change No change Acquired IPR&D ~$0.4B No change No change SG&A Expense ~High-single digit % decline No change ~Mid to high-single digit % decline Operating Income ~$12.7B - $13.2B No change ~$13.0B - $13.4B Effective Tax Rate ~19% No change No change Diluted EPS ~$7.70 - $8.10 No change ~$7.95 - $8.25 GAAP Diluted EPS ~$5.95 - $6.35 ~$5.65 - $6.05 ~$5.85 - $6.15 This financial guidance excludes the impact of any expenses related to potential acquisitions or business development transactions that have not been executed, future fair value adjustments of equity securities and discrete tax charges or benefits associated with changes in tax related laws and guidelines as Gilead is unable to project such amounts. This guidance is subject to a number of risks and uncertainties. See Forward-Looking Statements on page 2. Please refer to the accompanying press release for GAAP to non-GAAP reconciliations. 2025 Guidance – P&L 25 • SG&A updated to reflect higher HIV sales and marketing expenses and other corporate expenses associated with higher FY25 base business expectations • No change to R&D expectations Non-GAAP Operating Expenses • EPS Guidance increased by $0.20 at midpoint Non-GAAP EPS • FY25 expectations reduced to ~$1B, reflecting current path of pandemic and lower hospitalization rates in 1H25 Veklury

• 26. $1B Dividends Paid in Q225 $527M Shares Repurchased in Q2251 5M shares at average $105.88 Continue to invest in our business and R&D pipeline while managing expenses Continue ordinary course partnerships and business development transactions Grow our dividend Repurchase shares to offset dilution and opportunistically reduce share count Capital Priorities Unchanged: Returned $1.5B in Q225 26 1. Repurchases of common stock under repurchase program. $6B New Share Repurchase Program Approved July 2025

• 27. Q&A Johanna Mercier Chief Commercial Officer Andrew Dickinson Chief Financial Officer Dietmar Berger, MD, PhD Chief Medical Officer Daniel O’Day Chairman & Chief Executive Officer Cindy Perettie EVP & Head of Kite

• 28. Clinical stage programs1 52 8 Potential clinical stage opt-in assets Kite Program Optionable Partner Program 28 Pipeline shown above as of end of Q225. FDA approved medicines shown: Livdelzi® for primary biliary cholangitis (accelerated approval). 1. Program count does not include potential partner opt-in programs or programs that have received both FDA and EC approval. Anito-cel - anitocabtagene autoleucel, Axi-cel - axicabtagene ciloleucel, BIC - bictegravir, DOM – domvanalimab, FL - follicular lymphoma, GI – gastrointestinal, HDV – hepatitis delta virus, HIV - human immunodeficiency virus, HER+/HER2-mBC - hormone receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer, HR – high risk, ISL - islatravir, LAI – long acting injectable, LAO – long acting oral, LBCL - large B-cell lymphoma, LEN - lenacapavir, mEC – metastatic endometrial cancer, MM – multiple myeloma, mNSCLC – metastatic non-small cell lung cancer, mTNBC – metastatic triple-negative breast cancer, PBC - primary biliary cholangitis, pembro – pembrolizumab, PrEP - pre-exposure prophylaxis, R/R – relapsed/refractory, SG - sacituzumab govitecan-hziy, TNBC – triple-negative breast cancer, ZIM – zimberelimab. PHASE 1 PHASE 2 PHASE 3, FILED, or APPROVED Oncology Inflammatory Disease Viral Disease Yeztugo® HIV PrEP LAI Hepcludex® HDV SG 1L mTNBC (PD-L1-) DOM + ZIM + chemo 1L mNSCLC Anito-cel 2-4L R/R MM SG + pembro 1L mTNBC (PD-L1+) SG 2L mEC SG + pembro adjuvant TNBC DOM + ZIM + chemo 1L Upper GI SG HR+/HER2- chemo-naïve mBC Axi-cel 2L+ HR FL BIC/LEN combo HIV Oral LEN/ISL combo HIV LAO SG + pembro 1L mNSCLC (PD-L1+ TPS>50%) Axi-cel 1L HR LBCL Robust Pipeline with Upcoming Catalysts SG SCLC

• 29. Clinical Program Indication Phase 1 Phase 2 Phase 3 Filed Updates since Q125 HIV Prevention Lenacapavir (PURPOSE 1 & 2) HIV PrEP LAI FDA approval granted HIV Treatment Bictegravir/lenacapavir oral combination (ARTISTRY-1 & -2) HIV Oral Islatravir/lenacapavir oral combination (ISLEND-1 &-2)1 HIV LAO HIV INSTI/capsid inhibitor (GS-4182/GS-1720) (WONDERS-1 & -2)2 HIV LAO Clinical Hold HIV capsid inhibitor (GS-3107) HIV LAO Lenacapavir + teropavimab + zinlirvimab3 HIV LAI HIV INSTI (GS-1219) HIV LAI HIV INSTI (GS-3242) HIV LAI HIV NRTTI (GS-1614)1 HIV LAI HIV Cure Teropavimab + zinlirvimab3,4 HIV Cure Vesatolimod (FRESH) HIV Cure HIV bispecific T-cell engager (GS-8588) HIV Cure 29 NDA approved and MAA filed Breakthrough Therapy Designation P PRIME Designation New listing since Q125 Change since Q125 Pipeline shown above as of end of Q225. 1. Subject to Gilead and Merck co-development and co-commercialization agreement. 2. Program timelines pending resolution of GS-1720 and GS-4182 clinical holds. 3. Teropavimab and zinlirvimab are broadly neutralizing antibody (bNAbs). 4. Non-Gilead sponsored trial(s) ongoing. HIV - human immunodeficiency virus, INSTI - integrase strand transfer inhibitor, LAI – long-acting injectable, LAO – long-acting oral, MAA - marketing authorization application, NDA – new drug application, NRTTI - nucleoside reverse transcriptase translocation inhibitor, PrEP - pre-exposure prophylaxis. Viral Diseases Pipeline 1/2

• 30. Clinical Program Indication Phase 1 Phase 2 Phase 3 Filed Updates since Q125 HDV Hepcludex® (MYR301) HDV HBV Cure Selgantolimod HBV Cure HBV therapeutic vaccine (GS-2829 + GS-6779) HBV Cure Emerging Viruses Obeldesivir RSV Removed from pipeline Obeldesivir Pediatric RSV Removed from pipeline Opt-ins Assembly Biosciences HBV, HDV, HSV 4 clinical stage programs 30 P BLA pending; MAA approved Pipeline shown above as of end of Q225. BLA – biologics license application, HBV – hepatitis B virus, HDV – hepatitis delta virus, HIV - human immunodeficiency virus, HSV – herpes simplex virus, MAA - marketing authorization application, RSV – respiratory syncytial virus. Viral Diseases Pipeline 2/2 Breakthrough Therapy Designation P PRIME Designation New listing since Q125 Change since Q125

• 31. Clinical Program Indication Phase 1 Phase 2 Phase 3 Filed Updates since Q125 Lymphoma Axicabtagene ciloleucel (ZUMA-22) 2L+ HR FL Axicabtagene ciloleucel (ZUMA-23) 1L HR LBCL Brexucabtagene autoleucel (ZUMA-4) Pediatric ALL/NHL CD19/CD20 bicistronic (KITE-363) R/R DLBCL CD19/CD20 bicistronic (KITE-753)1 R/R DLBCL CD19 CAR (KITE-197)1 R/R DLBCL Multiple Myeloma Anitocabtagene autoleucel (iMMagine-3)2 2-4L R/R MM Anitocabtagene autoleucel (iMMagine-1)2 4L + R/R MM 31 Pipeline shown above as of end of Q225. 1. Manufacturing innovation. 2. Global strategic collaboration to co-develop and co-commercialize with Arcellx. ALL - acute lymphocytic leukemia, DLBCL – diffuse large B-cell lymphoma, FL - follicular lymphoma, HR – high risk, LBCL - large B cell lymphoma, MM – multiple myeloma, NHL – non-Hodgkin’s lymphoma, R/R – relapsed/refractory. Cell Therapy Pipeline Breakthrough Therapy Designation P PRIME Designation New listing since Q125 Change since Q125

• 32. Clinical Program Indication Phase 1 Phase 2 Phase 3 Filed Updates since Q125 Breast Sacituzumab govitecan-hziy (ASCENT-03) 1L mTNBC (PD-L1-) Sacituzumab govitecan-hziy + pembrolizumab (ASCENT-04)1 1L mTNBC (PD-L1+) Sacituzumab govitecan-hziy + pembrolizumab (ASCENT-05) High risk adjuvant TNBC Sacituzumab govitecan-hziy (ASCENT-07) HR+/HER2- chemo-naïve mBC Lung & Thoracic Sacituzumab govitecan-hziy + pembrolizumab (EVOKE-03)1 1L mNSCLC (PD-L1+, TPS>50%) Domvanalimab + zimberelimab + chemo (STAR-121)2 1L mNSCLC Sacituzumab govitecan-hziy + pembrolizumab (EVOKE-02)1 1L mNSCLC Sacituzumab govitecan-hziy (EVOKE-SCLC-04) ES-SCLC New Lung cancer platform (VELOCITY-Lung3, EDGE-Lung2,4) NSCLC Domvanalimab + zimberelimab + chemo (VELOCITY-HNSCC)2 1L HNSCC Genitourinary Sacituzumab govitecan-hziy + combinations (TROPHY U-01) 1L mUC Gynecology Sacituzumab govitecan-hziy (ASCENT-GYN-01)5 2L mEC 32 Pipeline shown above as of end of Q225. 1. In collaboration with Merck. 2. In collaboration with Arcus Biosciences. 3. VELOCITY-Lung includes combinations of domvanalimab, etrumadenant, zimberelimab, and sacituzumab govitecanhziy. 4. EDGE-Lung includes immunotherapy-based combinations of quemliclustat, domvanalimab, and zimberelimab. 5. In collaboration with the GOG Foundation (GOG) and European Network of Gynecological Oncological Trial Groups (ENGOT). ES-SCLC – extensive stage - small cell lung cancer, HNSCC - head and neck squamous cell carcinoma, HR+/HER2-mBC - hormone receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer, mEC – metastatic endometrial cancer, mNSCLC – metastatic non-small cell lung cancer, mTNBC – metastatic triple-negative breast cancer, mUC - metastatic urothelial carcinoma, NSCLC – non-small cell lung cancer, TNBC – triple-negative breast cancer. Oncology Pipeline 1/2 Breakthrough Therapy Designation P PRIME Designation New listing since Q125 Change since Q125

• 33. Clinical Program Indication Phase 1 Phase 2 Phase 3 Filed Updates since Q125 Other Solid Tumor Sacituzumab govitecan-hziy (TROPiCS-03) Basket (Solid Tumors) Gastrointestinal Domvanalimab + zimberelimab + chemotherapy (STAR-221)1 1L Upper GI Etrumadenant + zimberelimab combinations (ARC-9)1 mCRC Removed from pipeline Quemliclustat +/- zimberelimab (ARC-8)1 mPDAC Removed from pipeline Advanced Cancers Denikitug (GS-1811) Advanced Cancers DGKα inhibitor (GS-9911) Advanced Cancers Removed from pipeline GS-2121 Advanced Cancers IL-2 variant (GS-4528) Advanced Cancers IL-18BP (GS-0321)2 Advanced Cancers Masked IL-12 (XTX301)3 Advanced Cancers MCL1 inhibitor (GS-9716) Advanced Cancers Removed from pipeline PARP1 inhibitor (GS-0201) Advanced Cancers Opt-ins Arcus Advanced Cancers 3 clinical stage programs Includes opt-in opportunity for Quemli MacroGenics Advanced Cancers 1 clinical stage program 33 Pipeline shown above as of end of Q225. 1. In collaboration with Arcus Biosciences. 2. Operationalized by Compugen. 3. Operationalized by Xilio. CCR8 – chemokine receptor 8, DGKα - diacylglycerol kinase alpha, GI – gastrointestinal, MCL1 – myeloid cell leukemia-1, mCRC – metastatic colorectal cancer, mPDAC - metastatic pancreatic ductal adenocarcinoma, PARP1 – poly (ADP-ribose) polymerase 1. Oncology Pipeline 2/2 Breakthrough Therapy Designation P PRIME Designation New listing since Q125 Change since Q125

• 34. Clinical Program Indication Phase 1 Phase 2 Phase 3 Filed Updates since Q125 Inflammatory Disease Edecesertib (COSMIC) Lupus Tilpisertib fosmecarbil (PALEKONA) IBD α4β7 inhibitor (SWIFT) IBD FXR agonist (GS-8670) IBD BTLA agonist (GS-0272) Inflammatory Diseases CD200R agonist (GS-5305) Inflammatory Diseases PD1 agonist (GS-0151) Inflammatory Diseases IRAK4 Degrader (GS-6791) Inflammatory Diseases New Metabolic Disease GLP-1R agonist (GS-4571) Metabolic Disease Fibrotic Disease Cilofexor/firsocostat/semaglutide combination (WAYFIND)1 NASH Removed from pipeline 34 Pipeline shown above as of end of Q225. 1. Clinical collaboration with Novo Nordisk. BTLA - B- and T-lymphocyte attenuator, GLP-1 – glucagon-like peptide-1, IBD – inflammatory bowel disease, MAA – marketing authorization application, NASH – nonalcoholic steatohepatitis, NDA – new drug application, PBC – primary biliary cholangitis, PD1 - program cell death protein 1. Inflammatory Diseases Pipeline Breakthrough Therapy Designation P PRIME Designation New listing since Q125 Change since Q125

• 35. As of in billions where applicable Jun 30, 2024 Sep 30, 2024 Dec 31, 2024 Mar 31, 2025 June 30, 2025 Total Debt, net $23.35 $23.25 $26.71 $24.95 $24.95 Debt Discounts, Premiums and Issuance Costs 0.16 0.16 0.19 0.18 0.18 Liability related to sale of future royalties1 (1.26) (1.15) (1.15) (1.14) (1.13) Total Adjusted Debt1 $22.25 $22.25 $25.75 $24.00 $24.00 Twelve Months Ended Jun 30, 2024 Sep 30, 2024 Dec 31, 2024 Mar 31, 2025 June 30, 2025 Net Income attributable to Gilead $1.05 $0.13 $0.48 $5.96 $6.31 Add: Interest Expense2 & Other (Income) expense, net 1.02 0.65 0.97 1.40 0.85 Add: Tax 0.50 0.06 0.21 0.86 0.89 Add: Depreciation 0.37 0.38 0.38 0.38 0.38 Add: Amortization 2.39 2.38 2.39 2.39 2.39 Add: Initial costs of externally developed IPR&D projects3 4.39 4.36 4.07 0.31 0.32 Add: Impairments 3.05 4.80 4.18 1.75 1.94 Adjusted EBITDA4 $12.77 $12.75 $12.68 $13.05 $13.08 Adjusted Debt to Adjusted EBITDA ratio4 ~1.74x ~1.75x ~2.03x ~1.84x ~1.83x 1. Adjusted Debt excludes funding agreements with: (1) RPI Finance Trust that was assumed as part of our acquisition of Immunomedics under which Immunomedics received cash in exchange for perpetual, tiered royalty payments on worldwide sales of Trodelvy, and (2) Abingworth LLP that was assumed as part of our acquisition of CymaBay under which CymaBay received funding in exchange for future regulatory and sales-based milestone payments upon regulatory approval of Seladelpar. 2. Total interest expense and amortization from all issued debt is expected to be in the range of $1.0B-$1.1B for the full year 2025. We retain the flexibility to refinance or to repay maturing debt. 3. Represents the initial costs of externally developed IPR&D projects with no alternative future use, acquired directly in a transaction other than a business combination, including upfront payments related to various collaborations and the initial costs of rights to IPR&D projects. 4. Adjusted EBITDA and Adjusted Debt to Adjusted EBITDA ratio are non-GAAP performance measures used by our investors and analysts to assess the overall operating performance in the context of financial leverage. GAAP to Non-GAAP Reconciliation of Outstanding Adjusted Debt and Adjusted EBITDA 35